Transmedics Group Stock Price, News & Analysis

TransMedics Group, Inc. (Nasdaq: TMDX), a medical technology company focused on transforming organ transplant therapy, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on Wednesday, September 4, 2024, at 1:05 p.m. Eastern Time at the Marriott Marquis New York.

Members of TransMedics' management team will engage in a fireside chat during the conference. Investors and interested parties can access a live and archived webcast of the discussion through the 'Investors' section of the TransMedics website. Additionally, the company's standard investor presentation is available for viewing on the same platform.

TransMedics Group, Inc. (Nasdaq: TMDX), a medical technology company focusing on organ transplant therapy, has announced the granting of inducement awards to four new employees. The grants, approved by the Compensation Committee and in line with Nasdaq Listing Rule 5635(c)(4), include:

- 3,073 non-qualified stock options with an exercise price of $170.28 per share
- 2,003 restricted stock units

The stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over three years. The restricted stock units will vest 25% annually over four years. Both are subject to continued employment and the terms of the TransMedics Group, Inc. Inducement Plan.

TransMedics Group, Inc. (Nasdaq: TMDX) reported strong financial results for Q2 2024. Total revenue reached $114.3 million, a 118% increase from Q2 2023. The company generated a net income of $12.2 million or $0.35 per diluted share. Key highlights include:

• Owned 15 aircraft as of June 30, 2024, with two more purchased in July
• Published 2023 ESG update report
• Gross margin was 61%, down from 70% in Q2 2023
• Operating expenses increased to $56.8 million
• Cash position improved to $362.8 million

TransMedics raised its full-year 2024 revenue guidance to $425-$445 million, representing 76-84% growth compared to the previous year.

TransMedics Group (Nasdaq: TMDX), a medical technology company revolutionizing organ transplant therapy, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event will take place at the InterContinental Boston Hotel on Tuesday, August 13, 2024.

Key details of the presentation:

• Date: Tuesday, August 13, 2024
• Time: 9:30 a.m. Eastern Standard Time
• Location: InterContinental Boston Hotel

Investors and interested parties can access a live and archived webcast of the fireside chat through the 'Investors' section of the TransMedics website at https://investors.transmedics.com/.

TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has granted inducement awards to 5 new employees. The awards include:

- 9,522 non-qualified stock options with an exercise price of $144.35
- 6,240 restricted stock units

These grants were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term and will vest over 4 years, with 25% vesting after the first year and the remainder vesting monthly over the next 3 years. The restricted stock units will vest in 25% increments annually over 4 years. Both awards are subject to continued employment with TransMedics.

TransMedics Group (Nasdaq: TMDX), a medical technology company focused on transforming organ transplant therapy, has announced its plans to release second quarter 2024 financial results on July 31, 2024, after market close. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the results. Investors can join the call by dialing (866) 807-9684 (domestic) or (412) 317-5415 (international) and requesting to join the TransMedics call. A live and archived webcast will be available on the company's investor relations website.

On June 18, 2024, TransMedics granted non-qualified stock options to purchase 1,002 shares of common stock and 657 restricted stock units (RSUs) to a new employee as a material inducement. These grants, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), are part of the TransMedics Inducement Plan. The stock options have an exercise price of $145.96 per share and a 10-year term. Vesting is structured with 25% of the shares vesting on the first anniversary of the employee's start date, and the remainder in equal monthly installments over three years. The RSUs follow a similar vesting schedule, with 25% vesting on the first four anniversaries of the employee's start date.

TransMedics, a medical technology company focused on organ transplant therapy, announced on May 17, 2024, the granting of stock options and restricted stock units to new employees. On May 14, 2024, the Compensation Committee approved the inducement grants, including non-qualified stock options to purchase 18,320 shares and 12,068 restricted stock units. The stock options have an exercise price of $132.44 per share, aligned with the stock's closing price on the Nasdaq Global Market that day. The stock options will vest 25% after the first year, with the remainder vesting monthly over three years. The restricted stock units will vest 25% each year over four years. These grants aim to attract and retain key talent.

TransMedics Group, Inc. reported net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the same period in 2023. The company generated a net income of $12.2 million or $0.35 per fully diluted share in Q1 2024. TransMedics highlighted OCS Heart and OCS Lung programs at the ISHLT annual meeting. With total revenue of $96.9 million and a gross margin of 62%, the company anticipates revenue growth in 2024, raising its revenue guidance to $390-400 million.